Nader is who he is, it's his nature. He's not going to
Nader is who he is, it's his nature. He's not going to change. He's got the upcoming call that he characterized as another exploration of the saga of Cytodyn to hopefully entice more investment. Maybe there will be updates or some kind of news that will clarify catalysts but it's definitely straight outta the same old playbook
And, to be honest, his unfiltered enthusiasm and willingness to hype and overshare has built a legion of not just monetarily but emotionally invested investors. But, as we all know, when tides turn the guy at the top is the lightning rod and with Nader it's not hard to come up with reasons why he deserves the heat.
Truthfully though, as I posted before, if you look at HGEN, they have a CEO that's the polar opposite temperamentally from Nader and their share price has gone into the toilet also. So whatever CEO's have done or not done, it may have not made much difference. The market is over the little covid underdogs. They may still have great promise but still have nothing tangible in the way of authorizations or approvals to show for almost 2 years of trying. And that's what built the share price up - covid. The alternate reality without the pandemic would probably be much different for CYDY.
The biggest issue staring us in the face with Nader though, is the fact that we should have authorized a bunch of new shares and done a massive financing when the price was high, but hindsight is 20/20. I watched an interview with another micro pharma CEO recently, Robert Foster of Hepion, and he said the biggest mistake in his first stint as a small pharma CEO was not raising money when it was there, even if investors may not have seen the long term value of big dilution when the money was available. He learned the hard way.
Right now Nader has shares to sell but he's got to sell only enough to scrape by because he doesn't want to burn through too many at this price. Hopefully things work themselves out and catalysts pump up the price enough to get a much nicer return on issuances but this is definitely the crisis point in the hero's journey. We all know things can change in a hurry so here's hoping for great news soon. With 12 new sites in Brazil, the possibility is there.
14
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...
Continue Reading
An Intriguing Move For Baidu's Class A Shares Well, here we go again, folks. Another move on the chessboard for Baidu. They've just walked their Class A ordinary shares onto the Shenzhen-Hong Kong and Shanghai-Hong Kong Stock Connects. As of today, September 7, 2026, mainland investors can now get their mitts on these shares more easily. It might not be a...
Continue Reading
The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...
Continue Reading
In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...
Continue Reading
Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....
Continue Reading
Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...
Continue Reading
Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...
Continue Reading
The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...
Continue Reading
Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...
Continue Reading
An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Prologis's Upcoming Quarterly Earnings Prologis (NYSE: PLD) is set to release its latest quarterly earnings report, and investors are eagerly awaiting the insights it will provide. As the company approaches its earnings announcement, analysts project an earnings per share (EPS) of $1.02, which serves as a benchmark for performance expectations. Investor...
Continue Reading
The recent U. S. employment report sent shockwaves through financial markets, reshaping how traders and investors eyed their portfolios. Stronger-than-expected job creation—with figures soaring over 100,000—meant one thing: the narrative on interest rates was about to change. Gone were the days of comfortably betting on rate cuts; now, everyone’s scrambling to...
Continue Reading
Suno Boosts Innovation for Creators by Acquiring WavTool Suno has recently made a significant move in the music industry with their acquisition of WavTool. This strategic decision aims to enhance their offerings for songwriters and producers, enabling them to create music that resonates with a broader audience. By integrating WavTool's advanced capabilities into their...
Continue Reading
Leqembi Approved for IV Maintenance Treatment BioArctic AB, a notable player in the biopharmaceutical sector, has made significant headlines with the approval of Leqembi (lecanemab) for intravenous (IV) maintenance treatment for Alzheimer’s disease in the United Kingdom. This groundbreaking decision was announced following rigorous evaluations by the Medicines and...
Continue Reading
Overview of Class Action Lawsuits for ATYR, MLTX, BAX, JHX Attention investors! If you’ve invested in aTyr Pharma Inc. (NASDAQ: ATYR), MoonLake Immunotherapeutics (NASDAQ: MLTX), Baxter International, Inc. (NYSE: BAX), or James Hardie Industries plc (NYSE: JHX), it’s important to be aware of significant class action lawsuits affecting your investments. These companies...
Continue Reading